/BIOG-B.ST

BIOG-B.ST Stock - BioGaia AB (publ)

Q: What is the analyst price target for BIOG-B.ST?

Analyst price target information is not currently available for BIOG-B.ST.

Q: What is BIOG-B.ST's market cap?

Market capitalization information is not currently available for BIOG-B.ST.

Healthcare|Drug Manufacturers - Specialty & Generic|STO

$102.40+1.29%

+$1.30 (+1.29%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $112.64

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BIOG-B.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.44

52W High$139.70

52W Low$93.20

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$1.42B	$1.30B	$1.10B	$785.11M	$747.08M
Gross Profit	$1.03B	$950.19M	$801.93M	$582.95M	$546.92M
Gross Margin	72.4%	73.3%	72.6%	74.3%	73.2%
Operating Income	$423.37M	$443.10M	$361.46M	$253.74M	$228.15M
Net Income	$351.39M	$365.35M	$373.77M	$196.27M	$179.73M
Net Margin	24.7%	28.2%	33.9%	25.0%	24.1%
EPS	$3.47	$3.62	$3.70	$1.94	$1.78

Company Overview

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylorithe gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

Visit Website

Earnings History & Surprises

BIOG-B.ST

Beat Rate

72%

Last 18 quarters

Avg Surprise

+24.4%

EPS vs Estimate

Beats / Misses

13/5

Last 12 quarters

Latest EPS

$0.65

Q4 2025

EPS Surprise History

Q1 24

+13.6%

$0.67vs$0.59

Q2 24

+26.0%

$1.21vs$0.96

Q3 24

+15.8%

$1.10vs$0.95

Q4 24

-43.8%

$0.36vs$0.64

Q1 25

+42.1%

$0.81vs$0.57

Q2 25

-1.3%

$0.79vs$0.80

Q3 25

+24.1%

$0.87vs$0.70

Q4 25

-18.6%

$0.65vs$0.80

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 5, 2026	—	—	—	—
Q1 2026	Feb 10, 2026	—	—	—	—
Q4 2025	Oct 22, 2025	$0.80	$0.65	-18.6%	✗ MISS
Q3 2025	Jul 18, 2025	$0.70	$0.87	+24.1%	✓ BEAT
Q2 2025	May 5, 2025	$0.80	$0.79	-1.3%	✗ MISS
Q1 2025	Feb 12, 2025	$0.57	$0.81	+42.1%	✓ BEAT
Q4 2024	Oct 22, 2024	$0.64	$0.36	-43.8%	✗ MISS
Q3 2024	Jul 23, 2024	$0.95	$1.10	+15.8%	✓ BEAT
Q2 2024	May 7, 2024	$0.96	$1.21	+26.0%	✓ BEAT
Q1 2024	Feb 7, 2024	$0.59	$0.67	+13.6%	✓ BEAT
Q4 2023	Oct 20, 2023	$0.78	$1.01	+29.5%	✓ BEAT
Q3 2023	Jul 21, 2023	$0.75	$0.80	+6.7%	✓ BEAT
Q2 2023	May 5, 2023	$0.88	$1.15	+30.7%	✓ BEAT
Q1 2023	Feb 3, 2023	$0.61	$1.38	+126.2%	✓ BEAT
Q4 2022	Oct 21, 2022	$0.48	$0.79	+64.6%	✓ BEAT
Q3 2022	Jul 22, 2022	$0.46	$0.78	+69.6%	✓ BEAT
Q2 2022	May 6, 2022	$0.64	$0.76	+18.8%	✓ BEAT
Q1 2022	Feb 4, 2022	$0.68	$0.38	-44.1%	✗ MISS
Q4 2021	Oct 21, 2021	$0.28	$0.52	+85.7%	✓ BEAT
Q3 2021	Aug 12, 2021	$0.58	$0.54	-6.9%	✗ MISS

Frequently Asked Questions about BIOG-B.ST

What is BIOG-B.ST's current stock price?

BioGaia AB (publ) (BIOG-B.ST) is currently trading at $102.40 per share. The stock has moved +1.29% today.

What is the analyst price target for BIOG-B.ST?

No analyst price targets are currently available for this stock.

What sector is BioGaia AB (publ) in?

BioGaia AB (publ) operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the STO exchange.

What is BIOG-B.ST's market cap?

BioGaia AB (publ) has a market capitalization of $10.09 billion, making it a large-cap company.

Does BIOG-B.ST pay dividends?

No, BioGaia AB (publ) does not currently pay a dividend to shareholders.